January 20, 2026
Pfizer Exits ViiV Healthcare as Shionogi Doubles Stake in $2.13 Billion Deal
Pfizer; Shionogi; ViiV Healthcare; GSK; HIV; stake sale
GSK Acquires RAPT Therapeutics for $2.2 Billion to Advance Food Allergy Drug Ozureprubart
GSK; RAPT Therapeutics; acquisition; $2.2B; ozureprubart; food allergy; anti-IgE; immunology
AstraZeneca Acquires Complete Global Rights to AbelZeta’s C-CAR031 CAR-T Therapy for Up to $630 Million
AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC
Moderna and Merck Report Sustained 49% Risk Reduction in Recurrence or Death with mRNA-Keytruda Combo at Five Years in Melanoma Trial
Moderna; Merck; Keytruda; intisemeran autogene; mRNA-4157; melanoma; recurrence-free survival; Phase 2b
No Recent News on BetterHelp’s Quiet AI Expansion; Focus Remains on Insurance Growth
Teladoc; BetterHelp; insurance expansion; UpLift acquisition; mental health; revenue decline
Makary Proposes Higher FDA User Fees for Non-US Phase I Trials to Counter China Biotech
Makary; FDA; user fees; China; biotech; Phase I trials; America First
Corvus Pharmaceuticals Reports Positive Phase 1 Data for Soquelitinib in Atopic Dermatitis, Exceeding Expectations
Corvus Pharmaceuticals; soquelitinib; Phase 1; atopic dermatitis; EASI reduction; ITK inhibitor
Merck & Co. Partners with Guardant Health on Multi-Year Oncology Collaboration for Biomarker-Driven Cancer Therapies
Merck; Guardant Health; oncology collaboration; liquid biopsy; companion diagnostics; Infinity Smart platform; Keytruda
Nxera Pharma Reports Positive Phase 3 Results for Daridorexant in South Korea Insomnia Trial
Nxera Pharma; daridorexant; Phase 3; insomnia; South Korea; QUVIVIQ
Bayer and Vanderbilt University Medical Center Announce Five-Year Collaboration to Advance Cardiovascular and Kidney Disease Treatments
Bayer; Vanderbilt University Medical Center; cardiovascular diseases; kidney diseases; collaboration; precision medicine; BioVU